CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 enrolled
Drug / intervention
celecoxib +1 moredrug
Likely dose
celecoxib 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00291694
NCT00291694Phase 2Completed
CompareCT.gov

A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo

Carol Fabian, MD·interventional·Posted Feb 14, 2006·Updated Nov 7, 2016

In Brief

A Phase 2 clinical trial evaluating celecoxib and placebo for Breast Cancer. Completed, enrolled 72 participants across 1 site.

Detailed Summary

To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsSusan G. Komen Breast Cancer Foundation

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 14, 2006
Enrollment StartApr 1, 2003
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 20.4 years ago

Interventions

celecoxibdrug

Celecoxib 400 mg BID

placeboother

placebo